Add Formweb to your mobile device
Approved Formulary
Search results for:
dexrazoxane
dexrazoxane
Brand names: Totect, Zinecard
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 500 mg |
Display Protective Agents Class:
925600
Medication comments:
| Per policy, these hazardous drugs have special waste requirements. | |
|---|---|
| Generic (Brand) | Waste Requirements |
| dexrazoxane (Totect, Zinecard) | Hazardous Waste ⇒ BLACK BUCKET |
| USP <800> Hazardous Drugs | ||||||
|---|---|---|---|---|---|---|
| Per Policy, these drugs have special handling requirements (any drug with an "AOR" is exempt from these requirements under normal circumstances). | ||||||
| generic (Brand) Route | Relative Risk Level | AOR? | NIOSH 2024 Table | MSHI?↑ | Warnings | |
| dexrazoxane (Totect, Zinecard) IV | High | N/A | 1↑ | Yes | ||
| NIOSH Supplemental information (2016): secondary malignancies observed in patients treated long term with Razoxane (a racemic mixture containing dexrazoxane); genotoxic in vitro and in vivo; in laboratory studies, testicular atrophy observed at or below the human dose FDA Pregancy Category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks; | ||||||
Last updated: May. 27, 2025
- Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug